

New York Cardiovascular Symposium

The Annual Update for the
Cardiovascular Clinician

Virtual



SATURDAY, DECEMBER 12 – SUNDAY, DECEMBER 13, 2020

THE NEW YORK CARDIOVASCULAR SYMPOSIUM 2020

(Preliminary as of September 14, 2020)

Saturday, December 12, 2020

All times are Eastern Standard Time

Welcome

7:45 a.m. – 8:00 a.m.

Cathleen C. Gates

Interim, Chief Executive Officer

American College of Cardiology

Athena Poppas, MD, FACC

President

American College of Cardiology

Norma Keller, MD, FACC

President, New York State Chapter

American College of Cardiology

Cardiovascular & Coronary Artery Disease — Challenges in 2020

Session I: Evolving New Frontiers Ready for Practice

Chair: Athena Poppas, MD, FACC

8:00 a.m. – 8:25 a.m.

Clinical, Genetic & Noninvasive Imaging (3D-US, PET, MRI) Stratification

Predicting Progression of CVD and Cognitive Dysfunction

Valentin Fuster, MD, PhD, MACC

New York, NY

8:25 a.m. – 8:50 a.m.

CTA Imaging in the Full Assessment of Coronary Disease

Noninvasive Approach to Plaque Anatomy, Ischemia & Risk

Patrick W. Serruys, MD, FACC

Rotterdam, Netherlands

8:50 a.m. – 9:15 a.m.

***Stratification of Angina due to Coronary Microvascular Dysfunction
Epicardial Spastic Phenomenon & INOCA in Context***

Divaka Perera, MD

London, England, United Kingdom

9:15 a.m. – 9:35 a.m.

Coronary 18F-Sodium Fluoride Uptake Imaging

Predicts Activity and Outcomes in Patients with Coronary Disease

Marc Dweck, MB ChB, PhD, FACC

Edinburgh, Scotland, United Kingdom

9:35 a.m. – 10:00 a.m.

Panel Discussion

Panelists: Drs. Dweck, Fuster, Perera and Serruys

10:00 a.m. – 10:25 a.m.

Break

Session II: Acute Coronary Syndrome Complexities

Chair: Deepak L. Bhatt, MD, MPH, FACC

10:25 a.m. – 10:45 a.m.

STEMI - PCI Complete Revascularization vs Culprit Lesion only

Multivessel Disease Without or With Cardiogenic Shock

Shamir Mehta, MD, FACC

Hamilton, ON, Canada

10:45 a.m. – 11:05 a.m.

COVID 19 - Acute Coronary / Myocardial Syndromes & Follow Up

Certainties & Uncertainties on Incidence, Pathogenesis & Management

Deepak L. Bhatt, MD, MPH, FACC

Boston, MA

11:05 a.m. – 11:35 a.m.

Antithrombotics in High vs Low Risk Patients & with vs Without PCI

Evolving Path Towards Monotherapy - For How Long, P2Y₁₂ Inhib.? vs NOACS

Roxana Mehran, MD, FACC

New York, NY

11:35 a.m. – 12:00 Noon

Panel Discussion

Panelists: Drs. Bhatt, Mehran and Mehta

12:00 Noon – 1:00 p.m.

Lunch Break

Session III: Chronic Coronary Disease, Systemic Arterial Disease, Stroke and Pulmonary Embolism
Chair: Dipti Itchhaporia, MD, FACC

1:00 p.m. – 1:25 p.m.

Stable Coronary Multivessel Disease

Five Variables - Clinical, Anatomy, LV, Ischemia, Microcirculation

Three Approaches of Managements - PCI vs CABG vs OMT

Valentin Fuster, MD, PhD, MACC

New York, NY

1:25 p.m. – 1:50 p.m.

Coronary & Systemic Arterial Disease –

The Role of New Oral Anticoagulants (NOACS)

John Eikelboom, MBBS

Hamilton, ON, Canada

1:50 p.m. – 2:15 p.m.

Ischemic Strokes & Cerebral Hemorrhage

Acute Management vs Primary & Secondary Prevention

Priyank Khandelwal, MD

Newark, NJ

2:15 p.m. – 2:40 p.m.

Pulmonary Emboli - Diagnosis Based on Suspicion

Management Based on the Acute Severity and Degree of Chronic PH

Samuel Z. Goldhaber, MD, FACC

Boston, MA

2:40 p.m. – 3:05 p.m.

Panel Discussion

Panelists: Drs. Eikelboom, Fuster, Goldhaber and Khandelwal

3:05 p.m. – 3:30 p.m.

Break

Session IV: Trends and Challenges of Approaching Prevention – Health Factors
Chair: Pamela B. Morris, MD, FACC

3:30 p.m. – 3:55 p.m.

Obesity – From Genetics & Behavior to Pharmacotherapy & Bariatric Surgery

Carl J. Lavie, MD, FACC

New Orleans, LA

3:55 p.m. – 4:20 p.m.

Lipid-Modifying Agents - From Statins to PCSK9 Inhibitors

Neil J. Stone, MD, FACC

Chicago, IL

4:20 p.m. – 4:45 p.m.

Diabetic Agents – From Metformin To SGLT2 Inhib. & GLP1 Receptor Agonists

David Preiss, MD, PhD

Oxford, England, United Kingdom

4:45 p.m. – 5:10 p.m.

Changing Patterns of Mortality And Their Causes --- The PURE Study in 21 Countries

Salim Yusuf, DPhil, FACC

Hamilton, ON, Canada

5:10 p.m. – 5:35 p.m.

The Present Global Burden of Cardiovascular Diseases and Risk Factors

George A. Mensah, MD, FACC

Bethesda, MD

5:35 p.m. – 6:00 p.m.

Panel Discussion

Panelists: Drs. Lavie, Mensah, Preiss, Stone and Yusuf

6:00 p.m. Adjourn

Sunday, December 13, 2020

All times are Eastern Standard Time

Cardio-Pulmonary and Electrical Failure 2020

Session V: Myocardial Disease and Heart Failure; Basis for Management

Chair: Clyde W. Yancy, MD, MACC

8:00 a.m. – 8:20 a.m.

Evolving Imaging (MRI, PET) for 7 Myocardial Diseases

Myocarditis, Dilated CM, Hypertrophic CM, Noncompaction LV,

Amyloid CM, Sarcoid & Takotsubo

Diagnostic & Prognostic Tools

Jeroen J. Bax, MD, PhD, FACC

Leiden, Netherlands

8:20 a.m. – 8:40 a.m.

Evolving Clinical Genetics & Omics in 7 Myocardial Diseases

Which Subgroup or When Should be Gene Tested

William J. McKenna, MD, FACC

London, England, United Kingdom

8:40 a.m. – 9:00 a.m.

Evolving Understanding of HFrEF vs HFpEF vs HFmrEF Phenotypes

Therapeutic Role of SGLT2 Inhibitors & ARNIs in the 3 Entities

Clyde W. Yancy, MD, MACC

Chicago, IL

9:00 a.m. – 9:20 a.m.

***Evolving Therapeutic Approaches to 4 Challenging Cardiomyopathies:
Myocarditis, Takotsubo, AL/TTR Amyloid and Non-Compaction LV
Mathew S. Maurer, MD, FACC
New York, NY***

9:20 a.m. – 9:40 a.m.

***Assist Devices in Cardiac Decompensation – The 2 Challenges:
1. LVAD Indications: Not too Early since Risks are High, but Not too Late,
2. Assist Devices in the acute Decompensation – Impella vs ECMO
Sean P. Pinney, MD, FACC
Chicago, IL***

9:40 a.m. – 10:10 a.m.

***Panel Discussion
Panelists: Drs. Bax, Maurer, McKenna, Pinney and Yancy***

10:10 a.m. – 10:35 a.m.

Break

Session VI: Rhythm Disorders, Contemporary and Future Topics of Focus

Chair: Vivek Y. Reddy, MD

10:35 a.m. – 11:00 a.m.

***Atrial Fibrillation 2020 – 14 Clinical Challenges
Quality of Life & Preventing Stroke
Valentin Fuster, MD, PhD, MACC
New York, NY***

11:00 a.m. – 11:25 a.m.

***Atrial Fibrillation - Catheter Ablation
Who?, When?, How?, Results? (CABANA & Others).
Vivek Y. Reddy, MD
New York, NY***

11:25 a.m. – 11:45 a.m.

***Atrial Fibrillation - Left Atrial Appendage Closure
Who?, When?, How?, Results?
Jens Erik Nielsen-Kudsk, MD
Aarhus, Denmark***

11:45 a.m. – 12:10 p.m.

***Ventricular Tachycardia - Catheter Ablation
Who?, When?, How?, Results?
Karl-Heinz Kuck, MD
Hamburg, Germany***

12:10 p.m. – 12:35 p.m.

Device Therapeutic Approaches CRTs Strict Indications, Subcutaneous ICDs, Leadless Pacemakers Follow-up Observations

**Christophe Leclercq, MD
Rennes, France**

12:35 p.m. – 1:00 p.m.

Panel Discussion

Panelists: Drs. Fuster, Kuck, Leclercq, Nielsen-Kudsk and Reddy

1:00 p.m. – 2:00 p.m.

Lunch Break

Valvular Heart Disease and Aorta — Challenges in 2020

Session VII: Management of Aortic Valve Disease and Aorta

Chair: Rick A. Nishimura, MD, MACC

2:00 p.m. – 2:30 p.m.

Aortic Valvular Stenosis: 3 Diagnostic and Management Challenges

- **Congenital vs Senile,**
- **Asymptomatic vs Symptomatic,**
- **Low Flow/Low Gradient: CM 2ary to AS vs Dilated vs Restrictive**

Presentation: (15 minutes)

**Robert O. Bonow, MD, MACC
Chicago, IL**

Critical Commentary: (15 minutes)

Drs. David H. Adams, Patrick T. O’Gara, Josep Rodes-Cabau and Samin K. Sharma

2:30 p.m. – 3:00 p.m.

Aortic Regurgitation: 3 Diagnostic and Management Challenges

- **Associated or not Dilatation of the Aorta**
- **Asymptomatic vs Symptomatic**
- **EF Low/Intermediate vs Normal**

Presentation: (15 minutes)

**Rick A. Nishimura, MD, MACC
Rochester, MN**

Critical Commentary: (15 minutes)

Drs. Ismail El-Hamamsy, David H. Adams, Robert O. Bonow, Patrick T. O’Gara, Josep Rodes-Cabau and Samin K. Sharma

3:00 p.m. – 3:30 p.m.

**The Dilated Thoracic & Abdominal Aorta and Complicating Dissection
Evolving Understanding of the Basic Biology & Management**

Presentation: (15 minutes)

Valentin Fuster, MD, PhD, MACC

New York, NY

Critical Commentary: (15 minutes)

Ismail El-Hamamsy, MD, PhD,

New York, NY

3:30 p.m. – 3:50 p.m.

Break

Session VIII: Management of Mitral Regurgitation, Tricuspid Regurgitation and Hypertrophic Cardiomyopathy

Chair: David H. Adams, MD, FACC

3:50 p.m. – 4:20 p.m.

Mitral Regurgitation: 3 Diagnostic and Management Challenges

- **Primary vs Secondary**
- **Asymptomatic vs Symptomatic**
- **EF Low/Intermediate vs Normal**

Presentation: (15 minutes)

Patrick T. O’Gara, MD, MACC

Boston, MA

Critical Commentary: (15 minutes)

Drs. Robert O. Bonow, Rick A. Nishimura, Josep Rodes-Cabau & Samin K. Sharma

4:20 p.m. – 4:50 p.m.

Tricuspid Regurgitation: 3 Diagnostic and Management Challenges

- **Primary vs Secondary to Pulmonary Hypertension**
- **Residual from Previous Left Sided Valvular Surgery or not**
- **Symptomatic with RVEF Low/Intermediate vs Normal**

Presentation: (15 minutes)

Josep Rodes-Cabau, MD

Quebec, QB, Canada

Critical Commentary: (15 minutes)

Drs. Robert O. Bonow, Rick A. Nishimura, Patrick T. O’Gara and Samin K. Sharma

4:50 p.m. – 5:20 p.m.

Hypertrophic Cardiomyopathy – 5 Challenging Questions

Genetics/Acquired, Myectomy Types, CD, Apical/Aneurysm

Presentation: (15 minutes)

Rick A. Nishimura, MD, MACC

Rochester, MN

Critical Commentary: (15 minutes)

Drs. Robert O. Bonow, Patrick T. O’Gara, Josep Rodes-Cabau, and Samin K. Sharma

5:20 p.m.

Adjourn